CA
NZ
UK
AU
IND
US
The U.S. cannabis sector in mid-September 2026 is defined by two parallel federal tracks: progress on marijuana rescheduling and a looming crackdown on most hemp-derived THC products. State markets keep growing, but operators still face oversupply, thin margins, and uneven access to capital.
BioVie Inc. (NASDAQ: BIVI) shares closed up 6% at $2.05 after the company entered into an at-the-market offering agreement with A.G.P. to issue and sell up to $6.46 million of Class A common stock for working capital and general corporate needs.
Contineum Therapeutics, Inc. (NASDAQ: CTNM) reported that its Johnson & Johnson-partnered asset, JNJ-5120/PIPE-307, missed its primary endpoint within the Phase 2 MOONLIGHT-1 major depressive disorder study, failing to show a statistically significant MADRS total score reduction against placebo at Day 5.
Several biotech names posted positive clinical or regulatory developments in the same news cycle, spanning anxiety disorder, infectious disease, obesity, cardiomyopathy, neuro-oncology imaging, andManufacturingoperations.
A separate cluster of biotech names moved on financing actions, corporate restructuring, and one clinical trial miss, spanning gene editing, cancer immunotherapy, industrial biotech, oncology, Long COVID, and depression.
Telix Pharmaceuticals Limited (NASDAQ: TLX) announced FDA approval of Pixclara (TLX101-CDx), marking the first targeted FET-PET agent cleared in the U.S. for glioma characterization across adult and pediatric populations.
PDS Biotechnology Corporation (NASDAQ: PDSB) shares closed up 35% at $0.40 after the company completed the initial closing of an approximately $11.3 million PIPE led by Nant Capital.
Dyadic International, Inc. (NASDAQ: DYAI) shares closed down 13% at $0.42 after the company submitted a resale prospectus registering up to 3.625 million shares for selling stockholders.
Tyra Biosciences, Inc. (NASDAQ: TYRA) shares closed up 14% at $25.07 after the company announced the pricing of a $400 million underwritten public offering featuring common stock alongside pre-funded warrants at $22.03 per share equivalent, spearheaded by RACapitalalongside broad institutional backing.
Cellectis S.A. (NASDAQ: CLLS) shares closed down 41% at $1.83 after the company announced a strategic pivot toward in vivo gene-editing programs, focusing resources on .HEAL-101 for APOC3 in severe hypertriglyceridemia and .HEAL-201 for PCSK9 in severe hypercholesterolemia.
Please wait processing your request...